Concerns & Risks -- 7/10
Favorable risk profile. FMS is the global #1 in dialysis and, with DaVita, half of an ~80% U.S. duopoly —
a leader-in-a-stable-market profile. Valuation sits below its only true peer on the primary metric, China
exposure is immaterial (~2-3% of group sales), and there are concrete near-term catalysts (5008X/HVHDF
rollout, FME25+ savings). The offsetting risk is concentrated in U.S. regulation/reimbursement, not
geopolitics: the temporary TDAPA contribution that inflated 2025 earnings phases out in H2 2026, creating a
transition-year earnings air-pocket. A genuine overhang — but known, quantified, and transitory.
Weight: 15%
Valuation
Below Peer
~6.0x EV/EBITDA vs DaVita ~6.9x
Discount
TDAPA Phase-Out
~€300m+
Rolls off H2 2026
Transition year
China Exposure
~2-3%
Of group sales
Immaterial
Consensus
2/3/2
Buy / Hold / Sell — mixed
Contested, low expectations
Valuation -- EV/EBITDA primary (P/E secondary)
| Metric | FY+1 Estimate | FMS Multiple | Peer Avg (DaVita) |
|---|---|---|---|
| EV/EBITDA (FY2026E) | EBITDA implied from ~17.9% margin on ~$19.8B rev | ~6.0x | ~6.9x |
| P/E (FY2026E) | EPS $2.03 (consensus, USD) | ~11.5x | ~12.9-13.3x |
| EV/Sales (TTM) | Rev ~$19.6B | ~1.07x | n/a |
FMS trades below DaVita on both EV/EBITDA (~6.0x vs ~6.9x) and forward
P/E (~11.5x vs ~13x). The bear pins the discount on FMS's heavier, lower-margin manufacturing
(Care Enablement) footprint and messier multi-segment restructuring vs DaVita's cleaner pure-play model.
EPS basis note: FY25 EPS ex-SI of €4.28 and FY26E ~$2.03 (USD) are not directly comparable —
different currency and reported-vs-ex-SI basis.
Market data: FMP /stable, 2026-06-25 (P/E TTM 12.47x; EV/EBITDA TTM 5.99x; EV ~$20.77B). Peer multiples:
DaVita per valueinvesting.io
(EV/EBITDA 6.90x) and TIKR P/E ~12.9-13.3x.
China exposure (% of sales)
| Item | Figure | Source |
|---|---|---|
| China as % of Care Enablement revenue | 7%-10% | Q4'25 transcript (Giza) |
| FY2025 Care Enablement revenue | €5,476.2m | Daloopa |
| Implied China revenue | ~€383m-548m | calc |
| FY2025 group revenue | €19,627.6m | Daloopa |
| China as % of GROUP sales | ~2.0%-2.8% | calc |
| China EBIT impact 2025 | -€50m (VBP/tender delays); lower 2026 | Q4'25 transcript |
China is immaterial to the group (~2-3% of sales). It is a manageable, declining headwind within one
segment — well below the rubric's 10% threshold.
Catalysts
| Catalyst | Timing | What it does |
|---|---|---|
| 5008X / high-volume HDF rollout | 2026-2028 | Largest clinic-infrastructure transition in company history; ~20% of US installed base + 36,000 patients in 2026; reduces mortality/missed treatments — benefits ramp into 2027-28 |
| FME25+ savings | 2026-2027 | €250m incremental savings in 2026; €1.2B cumulative by end-2027 |
| GLP-1 = tailwind, not threat | 2026+ | ESRD patients on GLP-1 now support the path back to 2%+ same-market treatment growth; the 2023-24 GLP-1 fear has inverted to opportunity |
| Value-Based Care inflection | done/ongoing | First breakeven year in 2025 (+€3m vs -€28m in 2024) |
| €1B buyback | ongoing | First €586m tranche done 2025; fresh ~€1B program launched May 2026 — supports EPS |
Regulatory / political risk
| Risk | Read |
|---|---|
| TDAPA phase-out (US) | THE key near-term overhang: ~€220m phosphate-binder + ~€90m catheter-solution TDAPA benefit in 2025 begins phasing out H2 2026 → flat 2026 EBIT guidance, mid-teens underlying growth masked. Known and quantified, not a surprise. |
| CMS ESRD rate (US) | CY2026 base rate set at $281.71/treatment (Nov-2025 final rule) — modest, predictable annual update; not a shock. |
| ACA subsidy expiry (US) | Enhanced ACA subsidies expiring weigh on VBC/commercial mix; Q1 attrition lower than feared. |
| China VBP/tendering | -€50m EBIT in 2025, lower in 2026; affects ~2-3% of group sales. |
Bull case
Global #1 in a structurally protected US duopoly; valuation sits below the only true peer on both
EV/EBITDA and P/E despite a cleaner forward earnings algorithm (low-teens underlying OI CAGR ex-TDAPA
noise, 3-7% reported CAGR to 2028). The 5008X rollout and FME25+ are self-help levers management
controls, GLP-1 flipped from threat to tailwind, VBC just turned profitable, and the buyback compounds
EPS. China is a rounding error. If management hits the 2028 margin aspiration, the discount to DaVita
should close.
Bear case
2026 is an explicit transition/investment year: TDAPA benefits that flattered 2025 (a combined ~€300m+)
roll off in H2, guidance is flat EBIT, and the 5008X rollout adds OpEx headwind before benefits arrive —
so the "low-teens underlying" growth is invisible in reported numbers this year. FMS's discount to DaVita
is arguably deserved given its lower-margin manufacturing drag, flat US same-market treatment growth,
execution risk on the largest clinic conversion in its history, and a noisier multi-segment story. A bad
flu season or slower mortality normalization delays the return to 2%+ volume growth.
Score rationale
Score of 7/10. On the rubric's three pillars FMS is strong on two: China exposure is well below the 10% line (~2-3% of group sales, a shrinking headwind) and valuation is below peer average on the primary EV/EBITDA metric (~6.0x vs DaVita ~6.9x) and on forward P/E (~11.5x vs ~13x). It also carries concrete, management-controlled near-term catalysts (5008X rollout, FME25+ savings, GLP-1 turning into a tailwind, VBC at breakeven, an active buyback).
Why not higher: a genuine US regulatory/reimbursement overhang — the TDAPA contribution that inflated 2025 phases out in H2 2026, producing a flat-EBIT transition year that masks the low-teens underlying earnings algorithm.
What keeps it a 7 (not lower): that overhang is known, quantified and transitory rather than structural, so it caps but does not gut the score. Net: a leader, cheaply valued vs its only real peer, with clear catalysts and an immaterial China problem, held back by a one-year reimbursement air-pocket.
Data sourced from Daloopa (fundamentals) and FMP (market data/consensus).